![Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial | The British Journal of Psychiatry | Cambridge Core Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial | The British Journal of Psychiatry | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary-alt:20180606105343-16438-mediumThumb-S0007125000240397_fig1g.jpg?pub-status=live)
Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial | The British Journal of Psychiatry | Cambridge Core
![The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary - Malhi - 2020 - Bipolar Disorders - Wiley Online Library The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary - Malhi - 2020 - Bipolar Disorders - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/8fd58a15-c690-437a-8603-cc6bfd694f61/bdi13035-fig-0005-m.jpg)
The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders: Major depression summary - Malhi - 2020 - Bipolar Disorders - Wiley Online Library
![Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder - Leung - 2021 - Brain and Behavior - Wiley Online Library Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder - Leung - 2021 - Brain and Behavior - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/d4dacc56-85b1-477a-9402-ad3bd9176e39/brb32311-fig-0001-m.jpg)
Drug use evaluation: A two‐year retrospective review of the effectiveness and tolerability of agomelatine versus mirtazapine in patients with depressive disorder - Leung - 2021 - Brain and Behavior - Wiley Online Library
![PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale](https://www.researchgate.net/profile/Angel-Montejo/publication/23267285/figure/tbl1/AS:601666369900582@1520459849923/Summary-of-main-adverse-events-results_Q320.jpg)
PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale
![Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis - ScienceDirect Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0924977X19304237-gr2.jpg)
Efficacy and tolerability of pharmacological and non-pharmacological interventions in older patients with major depressive disorder: A systematic review, pairwise and network meta-analysis - ScienceDirect
![PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale](https://www.researchgate.net/profile/Guy-Goodwin-2/publication/281057776/figure/fig2/AS:327325435613186@1455051873136/B-Evolution-by-visit-of-the-PRSexDQ-total-score-in-volunteers-with-sexual-activity-at_Q320.jpg)
PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale
![Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial | The British Journal of Psychiatry | Cambridge Core Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial | The British Journal of Psychiatry | Cambridge Core](https://static.cambridge.org/binary/version/id/urn:cambridge.org:id:binary:20180606105214147-0711:S0007125000240397:S0007125000240397_tab4.gif?pub-status=live)
Agomelatine or placebo as adjunctive therapy to a mood stabiliser in bipolar I depression: Randomised double-blind placebo-controlled trial | The British Journal of Psychiatry | Cambridge Core
![Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. - Abstract - Europe PMC Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. - Abstract - Europe PMC](https://europepmc.org/articles/PMC5889788/bin/gr2.jpg)
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. - Abstract - Europe PMC
![PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale](https://i1.rgstatic.net/publication/281057776_Better_sexual_acceptability_of_agomelatine_25_and_50_mg_compared_to_escitalopram_20_mg_in_healthy_volunteers_A_9-week_placebo-controlled_study_using_the_PRSexDQ_scale/links/565d64cd08aeafc2aac77147/largepreview.png)
PDF) Better sexual acceptability of agomelatine (25 and 50 mg) compared to escitalopram (20 mg) in healthy volunteers. A 9-week, placebo-controlled study using the PRSexDQ scale
![A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia | Nature Medicine A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-020-0806-7/MediaObjects/41591_2020_806_Fig1_HTML.png)